PRogetto Salute Parma

  • End date
    Feb 24, 2022
  • participants needed
  • sponsor
    University of Parma
Updated on 24 January 2021
ct scan
lung cancer
diagnostic procedures
low-dose chest computed tomography
lung carcinoma


This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national).

Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam.

The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods.

Secondary objectives:

  1. To evaluate the use of local smoking cessation clinics and their effects in terms of smoking cessation (primary prevention)
  2. To evaluate the outcomes of the program in terms of number of patients with early (presymptomatic) lung cancer treated with minimally invasive surgery (secondary prevention)
  3. To evaluate the number of false positives and their diagnostic work-up (PET-CT, CT-guided biopsy, bronchoscopy)

Primary endpoint:

  • Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months

Secondary endpoints:

  • To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
  • To measure the variation in smoking habits in enrolled smokers
  • To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site
  • To measure the consequent demand for further diagnostic investigations and treatment
  • To measure the number of false positives

Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.

Inclusion criteria

  • Age between 50 and 75 years
  • Equivalent tobacco intoxication of 15 cigarettes per day for 25 years or 10 cigarettes per day for 30 years
  • Status of current smoker or ex-smoker for <10 years.

Exclusion criteria

Personal history of cancer within the prior 5 years

We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.

After closing and adjusting the database and before data analysis, a document called Statistical Analysis Plan (SAP) will be drawn up. It will consist of the following

  • Statistical methods planned in the study protocol;
  • Size of the sample;
  • Management of missing data;
  • Evaluation of the endpoints;
  • Statistical models that will be applied in the analysis. The socio-demographic characteristics of the enrolled subjects, the adopted organizational methods and the effects of the prevention program (endpoints) will be analyzed and described using tables and figures.

The project "PRogetto Salute Parma: Primary and secondary prevention of smoking-related lung cancer" will be started once approved by the institutional Ethics Committee and authorized by the General Manager. The study is expected to be carried out over 2 years (from the inclusion of the first subject), with an expected period of 1 year for the enrolment and 1 further year for follow-up.

Condition Pulmonary Disease, Smoking, Smoking Cessation, Lung Neoplasm, Bronchial Neoplasm, Lung Cancer, Lung Disease, Smoking Habit, smoking tobacco, smoking cessation therapy, carcinoma lung, lung carcinoma
Treatment Low-dose computed tomography (LDCT)
Clinical Study IdentifierNCT04282694
SponsorUniversity of Parma
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 50 yrs and 74 yrs?
Gender: Male or Female
Do you have any of these conditions: Lung Neoplasm or Bronchial Neoplasm or Pulmonary Disease or Lung Cancer or Smoking Cessation or Smoking Habit or Lung Disease or Smoking?
Do you have any of these conditions: smoking cessation therapy or Smoking Cessation or lung carcinoma or smoking tobacco or Smoking or Smoking Habit or Lung Disease or Lung Neoplasm or ca...?
Equivalent tobacco intoxication of 15 cigarettes per day for 25 years or 10 cigarettes per day for 30 years
Status of current smoker or ex-smoker for <10 years

Exclusion Criteria

Personal history of cancer within the prior 5 years
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note